Showing results (91-100 of 103) with videos related to
Sort By:
Pageof 11
ACS Nano|September 21, 2022
Imaging Phase Segregation in Nanoscale LiCoO2 Single ParticlesElliot J Fuller, David S Ashby, Celia Polop, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.Neuro-Oncology Advances|November 29, 2023
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastomaTracy T Batchelor, Minhee Won, Arnab Chakravarti, et al.Neuro-Oncology|November 11, 2017
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913Prakash Chinnaiyan, Minhee Won, Patrick Y Wen, et al.International Journal of Radiation Oncology, Biology, Physics|December 2, 2019
High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539C Leland Rogers, Minhee Won, Michael A Vogelbaum, et al.Neuro-Oncology|June 3, 2022
Low-risk meningioma: Initial outcomes from NRG Oncology/RTOG 0539C Leland Rogers, Stephanie L Pugh, Michael A Vogelbaum, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2022
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial TumorsAndrew B Lassman, Khê Hoang-Xuan, Mei-Yin C Polley, et al.JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.Journal of Neuro-Oncology|November 11, 2021
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825Nirav Patil, Eashwar Somasundaram, Kristin A Waite, et al.Pageof 11